Atlas Trials

A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 Injection

Clinical trial NCT06635798 · RECRUITING

Trial details

NCT number
NCT06635798
Sponsor
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Tetanus
Start date
2024-09-03
Primary completion
2024-12-04
Enrollment
582

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.